Date
- 2026 (1)
- 2025 (26)
- 2024 (41)
- 2023 (48)
- 2022 (26)
- 2021 (101)
- 2020 (61)
- 2019 (126)
- 2018 (40)
- 2017 (22)
- 2016 (24)
- 2015 (14)
- 2014 (22)
- 2013 (8)
- 2012 (3)
- 2010 (2)
- 2009 (11)
- 2008 (5)
- 2007 (12)
- 2006 (10)
- 2005 (14)
- 2004 (5)
- 2003 (2)
- 2002 (6)
- 2001 (3)
- 2000 (12)
- 1999 (5)
- 1998 (4)
- 1997 (1)
- 1996 (7)
- 1995 (2)
- 1994 (6)
- 1993 (6)
- 1991 (20)
Sponsor content
696 result(s) found, displaying 41 to 50
-
Australian public assessment report (AusPar)Xenpozyme (olipudase alfa) was approved as an enzyme replacement therapy for the treatment of noncentral nervous system manifestations of acid sphingomyelinase deficiency in paediatric and adult patients with Niemann-Pick disease (types A/B or B).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BEYFORTUS nirsevimab 50mg in 0.5mL solution for injection prefilled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BEYFORTUS nirsevimab 100mg in 1mL solution for injection prefilled syringe.
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd